Saltigo continues the further development and expansion of its business relations with innovative USA-based pharmaceutical companies. At the Pharma ChemOutsourcing Exhibition in New Jersey, USA, taking place September 12 – 15, 2011, Saltigo will present itself as a supplier of services for the development and manufacture of exclusive API and advanced intermediates. Tony Jones, head of Marketing & Sales in Saltigo's Pharma business line, explains,"the Pharma ChemOutsourcing Conference is now in its sixth year and has quickly established itself as a key feature in the annual calendar for the pharmaceutical industry with particular focus on the smaller innovative biotech companies. Thus, this offers us an excellent opportunity to present our extensive services in the field of active pharmaceutical ingredient development and manufacture to potential customers attending this highly innovative pharmaceutical forum. Our focus includes all stages of product development starting from pre-clinical gram supply, through all clinical development phases and to commercial manufacture at multi ton scale."
In North America, LANXESS Corporation in the U.S. state of Washington operates the Redmond site for Saltigo. These capacities are now well established in the marketplace and cover pre-clinical and early clinical phase activities. This early phase capability perfectly compliments the extensive range of both scale-up and commercial manufacturing facilities available in Saltigo’s FDA approved site based in Leverkusen, Germany. The combination of both sites enables Saltigo to provide a unique portfolio of chemistries and manufacturing services performed under cGMP quality standards to meet the outsourcing requirements in the field of active ingredient research, development, registration and commercialization.
During the event in New Jersey, the company will present an overview of its extensive capabilities with particular emphasis on various ways the team can provide innovative solutions to the many challenges facing its customers.
Dr. Andreas Stolle, Head of Saltigo’s Business Line Pharma, comments,“the pharmaceutical industry continues to develop and encounter great change. With change comes the need for increasing innovation in all aspects of business including manufacturing, supply chain management, business processes and commercial agreements. At Saltigo, we constantly look at ways we can provide our customers with new approaches to the many challenges they face in their day to day activities. It is no longer just enough to rely on our well-known competence in chemistry and high quality systems. Today, we need to be more proactive to fully engage with our customers and together seek new solutions necessary to deliver sustainable and cost effective solutions. Working with smaller innovative biotech companies, such as the ones attending this event quite often provides an excellent opportunity to explore new ways of approaching business challenges, streamlining existing business processes and maximizing value from available resources.”
“Developing sustainable business relationships is a key goal for Saltigo and this can only be achieved by adopting a more partnership-based approach, with sharing of both the risks and rewards. Unlike many of the larger events, the format of Pharma ChemOutsourcing provides an ideal environment to have more strategic discussions with customers and leading industry experts”, Jones adds.
Saltigo is a leading supplier in the field of custom synthesis in the fields of pharmaceuticals, agrochemicals and specialties. Saltigo is part of the Advanced Industrial Intermediates segment, which generated sales of EUR 1,800 million in fiscal 2011. Saltigo, headquartered in Langenfeld, Germany, with production facilities in Leverkusen and Dormagen, employs around 1,400 staff worldwide. LANXESS Corporation also operates a further site for Saltigo in Redmond, Washington, United States.
Saltigo GmbH (saltigo.com) is a leading supplier in the field of custom synthesis. The company of specialty chemicals group LANXESS belongs to the Advanced Intermediates segment, which achieved total sales in 2010 of EUR 1,321million. Saltigo, headquartered in Langenfeld and with production facilities in Leverkusen and Dormagen, employs around 1,400 staff worldwide. LANXESS Corporation operates a site for Saltigo in Redmond (Washington, United States).